Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies

Launched by INSTITUTE OF APPLIED BIOSCIENCES · Oct 15, 2024

Keywords

ClinConnect Summary

This is an observational study in women with triple-negative breast cancer (TNBC) that aims to learn how the immune system, especially T cells, interacts with this cancer. Researchers will analyze T cell receptors (the parts of immune cells that recognize cancer) and other immune signals in tumor tissue and in blood. They will map where immune cells sit in the tumor and study the genes of these cells to see if certain patterns can help predict how the cancer will behave. The work is informational and not a test of a new treatment.

If you are eligible, about 150 women will be invited to participate. Participants must have a confirmed TNBC and be able to give written consent, with paired samples of blood and tumor tissue collected at diagnosis before any treatment. The study is being conducted in Thessaloniki, Greece, at the Institute of Applied Biosciences. It is an in-depth, long-term study, with primary results focusing on whether T cell receptor patterns can serve as biomarkers to predict outcomes, over roughly four years, with the study completing around 2028. No results are available yet, and this is purely observational, not a trial of a new therapy. If you want, you can look up the trial by its number NCT06646263 for more details.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • - Confirmed TNBC diagnosis
• Exclusion Criteria:
• • -